Quetiapine in Prevention of Delirium

Phase 2

Completed

• Conditions: Delirium
• Interventions: Drug: Quetiapine

• Registration Number: NCT05793632
• Lead Sponsor: Ain Shams University

Brief Summary

The aim is to study the effectiveness of Quetiapine in preventing delirium in the elderly patients with multiple risks for delirium.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-02-28
• Status Verified: 2023-03
• Study Start: 2023-03-01
• Study First Submitted QC: 2023-03-30
• Study First Posted: 2023-03-31
• Primary Completion: 2023-04-01
• Study Completion: 2023-04-15
• Last Update Submitted: 2023-07-06
• Last Update Posted: 2023-07-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Patients with anemia
• Sedated patients
• Hypotensive patients
• Immobilized patients
• Patients with visual or auditory impairment

Exclusion Criteria

• Patients or guardians refuse to participate
• Patients diagnosed with delirium
• Contraindication for delirium

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Quetiapine	Quetiapine	The patients with multiple risks for delirium will receive 25 mg/day PO

Primary Outcome Measures

Name	Time	Method
Quetiapine in preventing delirium	2 months	The presence of delirium will be monitored among the patients in the two groups using ICU-Confusion Assessment Method 7 score for delirium where a score of (0-2 = no delirium, 3-5 = mild to moderate delirium and a score \>5 = severe delirium)

Trial Locations

Locations (1)

Ain Shams University; 🇪🇬 Cairo, Egypt